Disability Related Feature Stories and Live Breaking News

Disability Nexus

Subscribe to Disability Nexus : eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Disability Nexus : homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

Top Stories

Monday 4 August, 2014 Frant Pub to Host Sloe Gin World Championships Where to pick the best sloes, wild mushroom foraging and Christmas wreath making with Moondown The George pub in Frant, East Sussex near Tunbridge Wells is to again host the Sloe Gin World Championships on Wednesday 10th December from 1.00pm. Artisan sloe gin makers from across the world will gather at the popular village pub on the Kent/Sussex border, to vie for the coveted Sloe Ginster World Champion title for 2014. This Christmas will mark the 6th year of the popular annual event which began when pub locals began arguing over the perfect sloe gin recipe. Dating back to around 1750, the traditional country pub, with two bars and restaurant, traditional English food with continental influences, hand drawn beers, oak beams, a large enclosed garden and dogs lying by log fires in winter – The George ... (more)

Adults with Autism sent hundreds of miles away from their families

Friday 5 September, 2014 Adults with Autism sent hundreds of miles away from their families National Leading Autism Campaigner & Ambassador for Autism, Kevin Healey, is outraged by the system that is currently not supporting people with Autism. This has resulted in many individuals being sent hundreds of miles away from their loved ones and therefore destroying families. The system is simply not geared up for Adults with Autism. Kevin Healey has been campaigning since December 2013 on behalf of both the Dyer Family in Wales and Leo Andrade-Martinez from London; both of these families have an adult on the autistic spectrum who has been sent hundreds of miles away from their home and city. Kevin Healey said: "I’m appalled that these parents are suffering on a daily basis in not having access to their children and it’s heartbreaking for all of them, because they can’t ... (more)

Les résultats de l'étude IMPROVE montrent que les bénéfices de Rebif(R) mesurés à l'examen IRM sont observés de manière précoce et durable lors du traitement de la forme rémittente-récidivante de sclérose en plaques

GENEVE, September 11 /PRNewswire/ -- Merck Serono, division de Merck KGaA (Darmstadt, Allemagne) a annoncé aujourd'hui les résultats de l'étude IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation), étude d'une durée de 40 semaines maintenant terminée. Les résultats montrent, au terme de 16 semaines de traitement par Rebif(R) (à raison de 44 microgrammes trois fois par semaine), une diminution significative de 69% du nombre de lésions cérébrales uniques combinées visibles, au moyen d'examen IRM, chez les patients atteints d'une forme rémittente-récidivante de sclérose en plaques (SEP-RR) par rapport au placebo. (3,0 versus 0,9 respectivement pour les groupes placebo et Rebif(R), p < 0.001) (critère principal). Une analyse post-hoc a montré que cet effet bénéfique pouvait être observé dès la 4ème semaine suivant l'initiation du traitement. Cette di... (more)

New Academy to Improve Health Care for the Spinal Cord Injured Supported by Paralyzed Veterans of America

DALLAS, Sept. 25 /PRNewswire-USNewswire/ -- A new interdisciplinary force for quality health care for people living with spinal cord injury/dysfunction (SCI/D), the Academy of Spinal Cord Injury Professionals, will officially launch this week. The new organization brings together physicians, nurses, psychologists, social workers, and rehabilitation therapists, and is supported by Paralyzed Veterans of America (Paralyzed Veterans), the veterans service and disabilities rights organization. "With the right partners, you can achieve anything," said Dr. Terrie Price, the newly-elected President of the Academy. "Together, our Academy of physicians, nurses, psychologists, social workers, and therapists will collaborate more closely to produce better treatment and quality-of-life outcomes for people living with spinal cord injury/dysfunction." With the tagline "Many M... (more)

Oxygen Biotherapeutics, Inc. Announces Expansion of Product Development Plan With Four Strategic Pillars

DURHAM, N.C., Oct. 20 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced its expanded product development plan. The new clinical development pipeline now encompasses seven indications for the Oxycyte(TM) emulsion: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. In the topical product area, the first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website with product shipment expected in about four weeks. The company plans to expand the cosmetic line into additional skin care products during 2010. The topical pipeline includes six additional topical... (more)

Eisai Plans to Continue Eritoran (E5564) Phase III Severe Sepsis Trial, Based on Interim Analysis That Evaluated Efficacy and Safety Data

LONDON, March 26, 2010 /PRNewswire/ -- Eisai Europe Ltd. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will continue enrolling to the planned 2,000 patients. As part of a planned interim analysis, an independent Data Monitoring Committee (DMC) has evaluated efficacy and safety data on the first 1,500 subjects to complete the 28-day follow-up in the Phase III ACCESS trial. After evaluating the efficacy and safety data, the DMC recommended continued enrollment to the planned goal of 2,000 patients, according to the current protocol. In addition, the DMC did not express safety concerns that would warrant stopping the trial at this time. The DMC evaluated data from the Phase III ACCESS trial, which is a global, randomized, double-blind, pl... (more)

Snapple Launches The Celebrity Apprentice-Inspired Teas Handcrafted by Bret Michaels and Holly Robinson Peete

PLANO, Texas, May 24 /PRNewswire-FirstCall/ -- Snapple says, "You're hired" to The Celebrity Apprentice-inspired teas handcrafted by finalists Bret Michaels and Holly Robinson Peete. Bret Michaels' Diet Snapple Trop-a-Rocka Tea and Holly Robinson Peete's Snapple Compassionberry Tea were created as part of the show's final task and are now available nationwide for a limited time only. To see a list of participating retailers, visit us online at Snapple.com. (Photo: http://www.newscom.com/cgi-bin/prnh/20100524/DA09427-a) (Photo: http://www.newscom.com/cgi-bin/prnh/20100524/DA09427-b) Snapple raised the boardroom stakes even further with a surprise $250,000 charity donation. Not only did each finalist go home with the same prize purse for their respective charities, the American Diabetes Association and the HollyRod Foundation, but their Snapple products will cont... (more)

Iconicast Revolutionizes Market Research and Product Rating

SANTA CLARA, CA -- (Marketwire) -- 04/18/12 -- Iconicast LLC, the company that humanizes digital communications, unveiled today at DEMO Spring 2012 the power of Smurks with Iconimetrix. The world's most human-like emoticon is now set to gauge and share the mood of a crowd with in-depth emotion and powerful back-end analytics, as opposed to a static line of 5 stars. The malleable mobile app is expected to dramatically disrupt the multi-billion dollar world of market research with its new geo-locating feature and leading edge technology that can average out the overall mood of just about any place, event or product. DEMO is the premier launch pad for emerging technologies to unveil their products to an audience of global press, VCs, angel investors and IT buyers. "This fun and innovative app is going to change the way the world reviews anything and change the way mark... (more)

Multiple Sclerosis (MS) specialty drug treatment cost projected to exceed $50,000 per person per year in 2016

ST. PAUL, Minn., Oct. 4, 2012 /PRNewswire/ -- A new study by pharmacy benefit manager Prime Therapeutics (Prime), in collaboration with Blue Cross and Blue Shield of Minnesota, found that the recent dramatic increase in Multiple Sclerosis (MS) specialty drug costs has resulted in the drug costs now accounting for more than two-thirds of the patients total cost of care. While many with MS have seen improved quality of life as a result of drug therapy, unfortunately these MS specialty drug cost increases were not associated with MS medical costs declining. These study findings will be presented today at the Academy of Managed Care Pharmacy's 2012 Educational Conference in Cincinnati, Ohio. According to the study, the average individual annual MS specialty drug cost was $28,152 and all other health care costs were $13,608 in 2010. The price for MS self-injectable spec... (more)

NICE Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting form of MS

OXFORD, England, January 22, 2014 /PRNewswire/ -- "MS treatments have come a long way in recent years and we're moving into a new era where people with MS and their clinicians have more choice and a new alternative to injections.  Having Aubagio available as an effective, simple, oral treatment option, which only needs to be taken once daily, is an exciting development for people with MS," commented Amy Bowen, Director of Service Development at the MS Trust. A new once daily, oral treatment, Aubagio® (teriflunomide) will now be available on the NHS for people with a relapsing form of multiple sclerosis (RRMS). This does not include patients with highly active or rapidly evolving severe relapsing-remitting MS.  Following today's National Institute for Health and Care Excellence (NICE) approval, adult patients with RRMS[1] will be able to have access to treatment with... (more)

New Appointment to Board of Directors and Scientific Advisory Committee at Egenix, Inc.

MILLBROOK, N.Y., Feb. 13, 2014 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Emmanuel Petricoin III, Ph.D. to its Board of Directors and Scientific Advisory Committee. Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program from 2001-2005, and a Senior Investigator within the Center for Biologics Evaluation and Research at the US Food and Drug Administration from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, and biomarker discover... (more)